ReviewAnnals of surgery2003
Clinical significance of angiogenesis in gastrointestinal cancers: a target for novel prognostic and therapeutic approaches.
Review in Annals of surgery, 2003. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 40 papers, 2 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
40 citing papers in PubMed, 2 syntheses or guidelines pooled it, 86 citations in OpenAlex.
- Prognostic value, clinicopathologic features and diagnostic accuracy of interleukin-8 in colorectal cancer: a meta-analysis.PloS one · 2015Pooled it
- Microvessel density and VEGF expression are prognostic factors in colorectal cancer. Meta-analysis of the literature.British journal of cancer · 2006Pooled it
- Biological and Targeted Therapies in the Multidisciplinary Management of Gastrointestinal Cancers.Cancers · 2026Review
- Regorafenib and Nifuroxazide exert enhanced suppression of hepatocellular carcinoma by inhibiting STAT3 and immune remodeling.Oncology reports · 2026Article
- Natural Products Targeting Angiogenesis and Tumor Microenvironment in Gastrointestinal Malignancies.Cells · 2026Review
- Triptolide suppresses IL-1β-induced expression of interleukin-8 by inhibiting ROS-Mediated ERK, AP-1, and NF-κB molecules in human gastric cancer AGS cells.Frontiers in oncology · 2024Article
- Protective Effect of Daidzein against Diethylnitrosamine/Carbon Tetrachloride-Induced Hepatocellular Carcinoma in Male Rats.Biology · 2023Article
- Angiogenesis and Hepatocellular Carcinoma: From Molecular Mechanisms to Systemic Therapies.Medicina (Kaunas, Lithuania) · 2023Review
- Role of vascular endothelial growth factor in radiotherapy resistance to esophageal squamous cell carcinoma.Journal of cancer research and clinical oncology · 2023Article
- The Roles of Epigenetic Regulation and the Tumor Microenvironment in the Mechanism of Resistance to Systemic Therapy in Hepatocellular Carcinoma.International journal of molecular sciences · 2023Review
- An emerging research: the role of hepatocellular carcinoma-derived exosomal circRNAs in the immune microenvironment.Frontiers in immunology · 2023Review
- Angiogenesis and immune checkpoint dual blockade: Opportunities and challenges for hepatocellular carcinoma therapy.World journal of gastroenterology · 2022Review
- Characterization of the Tumor Microenvironment and the Biological Processes with a Role in Prostatic Tumorigenesis.Biomedicines · 2022Article
- Human and mouse angiogenins: Emerging insights and potential opportunities.Frontiers in microbiology · 2022Review
- The Use of Cabozantinib in Advanced Hepatocellular Carcinoma in Hong Kong-A Territory-Wide Cohort Study.Cancers · 2021Article
- Role of platelet infiltration as independent prognostic marker for gastric adenocarcinomas.Journal of clinical laboratory analysis · 2020Article
- Plasminogen kringle 5 suppresses gastric cancer via regulating HIF-1α and GRP78.Cell death & disease · 2017Article
- The role of Jagged1/Notch pathway-mediated angiogenesis of hepatocarcinoma cellsOncology letters · 2017Article
- Prognostic significance of cyclooxygenase-2 expression in patients with hepatocellular carcinoma: a meta-analysis.Archives of medical science : AMS · 2016Review
- Prognostic significance of cyclooxygenase-2, epidermal growth factor receptor 1, and microvascular density in gastric cancer.Medical oncology (Northwood, London, England) · 2012Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors at 1 institution in 2 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
objectiveTo review the current data on the prognostic and therapeutic implications of tumor angiogenesis in gastrointestinal cancers. SUMMARY BACKGROUND DATA: Numerous studies have evaluated the prognostic value of tumor angiogenesis and the potential role of antiangiogenic therapy in various gastrointestinal cancers.
methodsA Medline literature search was conducted using "angiogenesis" or the names of various angiogenic factors in combination with the names of gastrointestinal cancers as the key words.
resultsSeveral studies have demonstrated a significant prognostic impact of tumor microvessel density and tumor expression of angiogenic factors, in particular vascular endothelial growth factor (VEGF), in various gastrointestinal cancers. A few studies have suggested that circulating VEGF might be a useful prognostic marker. However, results were not consistent across all studies and were limited by the retrospective nature of most studies. Antiangiogenic therapy has been shown to be effective against all common gastrointestinal cancers in preclinical studies, but currently there are few clinical data with regard to antiangiogenic therapy in gastrointestinal cancers.
conclusionsThere is mounting evidence to suggest that assessment of tumor angiogenesis might provide a novel approach of prognostication in patients with gastrointestinal cancers. However, current results from retrospective studies need to be validated by prospective studies. Antiangiogenic therapy is a promising strategy of cancer treatment that might be particularly useful in combination therapy for unresectable cancers or as an adjuvant therapy for resectable tumors.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.